Delta-Fly Pharma, Inc.
Delta-Fly Pharma, Inc. (4598.T) Stock Overview
Explore Delta-Fly Pharma, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
8.7B
P/E Ratio
-4.04
EPS (TTM)
$-218.28
ROE
-3.42%
4598.T Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Delta-Fly Pharma, Inc. (4598.T) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 67.59, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $483.04.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -4.04 and a market capitalization of 8.7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Company Profile
Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase III clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase I/II clinical trials for the treatment of solid cancer; DFP-11207, which has completed phase I clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, which is in preclinical trial to treat gastric/ovarian cancer. Delta-Fly Pharma, Inc. was incorporated in 2010 and is headquartered in Tokushima, Japan.
Kiyoshi Eshima
13
37-5 Nishikino, Tokushima
2018